
FDA grants orphan drug designation to Avrobio for its gene therapy
The US Food and Drug Administration (FDA) has granted orphan drug designation for gene therapy to Avrobio for the purpose of treating mucopolysaccharidosis type 2, also known as Hunter syndrome.